Overall, for NSCLC patients receiving anti-PD-1/PD-L1 monotherapy or combination therapy, ~6–71% of patients reported treatment-related fatigue (any grade), but the incidence of grade III/IV is low (<5%) (24, 45, 56). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.